SEHK:2327

Stock Analysis Report

Meilleure Health International Industry Group

Executive Summary

Meilleure Health International Industry Group Limited, an investment holding company, trades in health care products, and construction and chemical materials in Hong Kong and Mainland China.


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Meilleure Health International Industry Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2327's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-13.6%

2327

19.4%

HK Trade Distributors

5.3%

HK Market


1 Year Return

-76.3%

2327

-33.9%

HK Trade Distributors

-20.4%

HK Market

Return vs Industry: 2327 underperformed the Hong Kong Trade Distributors industry which returned -33.9% over the past year.

Return vs Market: 2327 underperformed the Hong Kong Market which returned -20.4% over the past year.


Shareholder returns

2327IndustryMarket
7 Day-13.6%19.4%5.3%
30 Day-28.7%-19.3%-8.5%
90 Day-38.0%-25.7%-14.7%
1 Year-76.3%-76.3%-31.3%-33.9%-17.6%-20.4%
3 Year-13.5%-14.9%-30.1%-36.3%-2.5%-12.3%
5 Year-37.0%-38.0%-59.5%-66.3%-5.7%-20.9%

Price Volatility Vs. Market

How volatile is Meilleure Health International Industry Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Meilleure Health International Industry Group undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 2327 (HK$0.29) is trading below our estimate of fair value (HK$3.29)

Significantly Below Fair Value: 2327 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 2327 is poor value based on its PE Ratio (13.6x) compared to the Trade Distributors industry average (9.2x).

PE vs Market: 2327 is poor value based on its PE Ratio (13.6x) compared to the Hong Kong market (9.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2327's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2327 is overvalued based on its PB Ratio (1x) compared to the HK Trade Distributors industry average (0.5x).


Next Steps

Future Growth

How is Meilleure Health International Industry Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

7.7%

Forecasted Capital Goods industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Meilleure Health International Industry Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Meilleure Health International Industry Group performed over the past 5 years?

42.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2327 has a large one-off gain of HK$61.6M impacting its June 30 2019 financial results.

Growing Profit Margin: 2327's current net profit margins (39.9%) are lower than last year (61.4%).


Past Earnings Growth Analysis

Earnings Trend: 2327's earnings have grown significantly by 42.1% per year over the past 5 years.

Accelerating Growth: 2327's earnings growth over the past year (1.9%) is below its 5-year average (42.1% per year).

Earnings vs Industry: 2327 earnings growth over the past year (1.9%) exceeded the Trade Distributors industry -0.08%.


Return on Equity

High ROE: 2327's Return on Equity (6.8%) is considered low.


Next Steps

Financial Health

How is Meilleure Health International Industry Group's financial position?


Financial Position Analysis

Short Term Liabilities: 2327's short term assets (HK$999.2M) exceed its short term liabilities (HK$300.9M).

Long Term Liabilities: 2327's short term assets (HK$999.2M) exceed its long term liabilities (HK$355.4M).


Debt to Equity History and Analysis

Debt Level: 2327's debt to equity ratio (31.3%) is considered satisfactory.

Reducing Debt: 2327's debt to equity ratio has reduced from 101% to 31.3% over the past 5 years.

Debt Coverage: 2327's debt is well covered by operating cash flow (32.7%).

Interest Coverage: 2327's interest payments on its debt are well covered by EBIT (4.2x coverage).


Balance Sheet

Inventory Level: 2327 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 2327's debt is covered by short term assets (assets are 2.7x debt).


Next Steps

Dividend

What is Meilleure Health International Industry Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2327's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2327's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2327's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2327's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 2327 is not paying a notable dividend for the Hong Kong market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2327's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Wen Chuan Zhou (36yo)

6.58s

Tenure

HK$540,000

Compensation

Ms. Wen Chuan Zhou has been the Chief Executive Officer and Executive Director of U-Home Group Holdings Limited since September 23, 2013. Ms. Zhou has been Vice Chairman of U-Home Group Holdings Limited. S ...


CEO Compensation Analysis

Compensation vs Market: Wen Chuan's total compensation ($USD69.67K) is below average for companies of similar size in the Hong Kong market ($USD301.13K).

Compensation vs Earnings: Wen Chuan's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Xuzhou Zhou
Co-Chairmen of the Board0.92yrHK$500.00k21.26% HK$268.0m
Wentao Zeng
Co-Chairmen & Executive Directorno dataHK$120.00k0.35% HK$4.4m
Wen Chuan Zhou
Vice Chairman & CEO6.58yrsHK$540.00k0.63% HK$7.9m
Shu Pai Li
CFO & Company Secretary0.75yrno datano data
Man Chun Chu
Human Resources Managerno datano datano data
Pu Feng
Chief of R&D Dept - Kunming Jida Pharmaceutical Company Ltd and Director of R&D Dept - Kunming Jidano datano datano data
Chen Bang Hua
President of Jiwa Rintech Holdings Limited and Executive Director of Jiwa Rintech Holdings Limitedno datano datano data
Man Fai Shek
Financial Controllerno datano datano data
Chun Xia Liu
Quality Director of KJP and Director of Yunnan Jiwa Pharm-Tech Co Ltdno datano datano data
Dong Mei Luo
Executive Assistant to Chairman and COO of Kunming Jida Pharmaceutical Company Ltdno datano datano data

3.8yrs

Average Tenure

53yo

Average Age

Experienced Management: 2327's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Xuzhou Zhou
Co-Chairmen of the Board0.92yrHK$500.00k21.26% HK$268.0m
Wentao Zeng
Co-Chairmen & Executive Directorno dataHK$120.00k0.35% HK$4.4m
Wen Chuan Zhou
Vice Chairman & CEO6.58yrsHK$540.00k0.63% HK$7.9m
Chen Bang Hua
President of Jiwa Rintech Holdings Limited and Executive Director of Jiwa Rintech Holdings Limitedno datano datano data
Chun Xia Liu
Quality Director of KJP and Director of Yunnan Jiwa Pharm-Tech Co Ltdno datano datano data
Chi Wai Chau
Independent Non-Executive Director6.67yrsHK$120.00k0.012% HK$150.5k
Zhenhua Mao
Non-Executive Director4.5yrsHK$120.00kno data
Guanjiang Gao
Independent Non-Executive Director6.67yrsHK$120.00kno data
Peng Wu
Independent Non-Executive Director0.92yrno datano data

4.5yrs

Average Tenure

57yo

Average Age

Experienced Board: 2327's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 2327 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.2%.


Top Shareholders

Company Information

Meilleure Health International Industry Group Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Meilleure Health International Industry Group Limited
  • Ticker: 2327
  • Exchange: SEHK
  • Founded:
  • Industry: Trading Companies and Distributors
  • Sector: Capital Goods
  • Market Cap: HK$1.260b
  • Shares outstanding: 4.27b
  • Website: https://www.meilleure.com.cn

Number of Employees


Location

  • Meilleure Health International Industry Group Limited
  • Tower 1
  • Unit 2906
  • Admiralty
  • Hong Kong

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
2327SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDOct 2003

Biography

Meilleure Health International Industry Group Limited, an investment holding company, trades in health care products, and construction and chemical materials in Hong Kong and Mainland China. It operates through six segments: Trading Business, Agency Service, Property Development, Property Investment and Leasing, Health Care Related Business, and Corporate. The company is also involved in the sale of medicines; leasing of building materials; property investment and leasing; provision of real estate agency services; and development of residential properties. In addition, it offers anti-aging health management services. The company was formerly known as U-Home Group Holdings Limited and changed its name to Meilleure Health International Industry Group Limited in March 2017. Meilleure Health International Industry Group Limited is headquartered in Admiralty, Hong Kong. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/01 12:47
End of Day Share Price2020/04/01 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.